Achieved a critical regulatory milestone with FDA approval of the Biologics License Application (BLA) for Avance, establishing it as the first and only approved biologic therapeutic for peripheral nerve discontinuities. Delivered 20.2% full-year revenue growth driven by double-digit expansion across all three target markets: Extremities, Oral Maxillofacial, and Breast. Reached a financial inflection point characterized by positive cash flow and improved profitability, enabling concentrated market deve ...